Kite updates KTE-C19 data
Kite Pharma Inc. (NASDAQ:KITE) gained $4.56 to $54.92 on Thursday after disclosing updated data from multiple trials of KTE-C19 in blood cancer patients who have been treated at NIH's National Cancer Institute. The disclosure came during a presentation at the JPMorgan Healthcare Conference in San Francisco.
As of Nov. 30, among 41 evaluable patients with aggressive non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), follicular lymphoma (FL) and mantle cell lymphoma (MCL), KTE-C19 led to an overall response rate (ORR) of 78%, with 54% of patients achieving a complete response. The company said 21 of 22 patients who achieved a complete response remain in remission. In 27 patients with aggressive NHL, KTE-C19 led to an ORR of 70%. ...